NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, announces that it will report third quarter financial results before market open on Friday, November 13. Management will hold an investment community conference call that morning to discuss financial results and provide a company update.
DATE: Friday, November 13, 2015
TIME: 8:30 a.m. (ET) / 5:30 a.m. (PT)
DIAL IN: 866-880-4999 from within the U.S.
702-495-1913 from outside the U.S.
Enter conference identification number 74214482
The live call also will be available at https://novabay.com/investors/events. A replay of the call will be available beginning two hours after its completion through 8:59 p.m. Eastern time November 27, 2015, by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S. and entering the conference identification number 74314482. The call will also be archived at https://novabay.com/investors/events.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals is a biopharmaceutical company focusing commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX™ Family of Products, including AVENOVA™ for the eye care market and NEUTROPHASE® for wound care, and CELLERX® for the aesthetic dermatology market, cleared by the FDA as a 510(k) medical device; and its AGANOCIDE® compounds, led by AURICLOSENE™.
NovaBay has partnerships in the U.S. and around the world with PBE, Inc. (U.S.), IHT, Inc. (U.S.), Galderma (France), Virbac (France), China Pioneer Pharma (China and Southeast Asia), Shin Poong Pharmaceuticals (South Korea), Biopharm (North African and the Middle East), Sarmedic Ltd (Israel), Ophthalmic Instrument Company (New Zealand) and Alpha Pharma LLC (the Ukraine).
NovaBay has received FDA-clearance of its intelli-Case, a highly innovative, easy-to-use device for use with hydrogen peroxide disinfection solutions with soft and Rigid Gas Permeable (RGP) contact lenses.
Stay informed on NovaBay’s progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website
From the Company
Thomas J. Paulson
Chief Financial Officer
Contact Thomas Paulson
Partner with NovaBay
Roy J. Wu
SVP Business Development
Contact Roy Wu